BioLife Solutions, Inc. (BLFS)

Market Cap	718.46M
Revenue (ttm)	143.27M
Net Income (ttm)	-66.43M
Shares Out	45.30M
EPS (ttm)	-1.52
PE Ratio	n/a
Forward PE	250.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	601,207
Open	15.03
Previous Close	15.14
Day's Range	14.84 - 16.04
52-Week Range	8.92 - 24.50
Beta	1.69
Analysts	Strong Buy
Price Target	24.80 (+56.37%)
Earnings Date	May 8, 2024

About BLFS

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproductio...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Nov 22, 1989
• Employees: 409
• Stock Exchange: NASDAQ
• Ticker Symbol: BLFS

Financial Performance

In 2023, BLFS's revenue was $143.27 million, a decrease of -11.43% compared to the previous year's $161.76 million. Losses were -$66.43 million, -52.49% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for BLFS stock is "Strong Buy." The 12-month stock price forecast is $24.8, which is an increase of 56.37% from the latest price.

Price Target

$24.8

(56.37% upside)

Analyst Consensus: Strong Buy